Abbott (ABT) is a large diversified U.S. company operating across four key segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. This structure makes the business less dependent on any single segment or market cycle, which is evident today as weakness in Nutrition and the post-COVID normalization in Diagnostics are partially offset by strong growth in Medical Devices and Established Pharmaceuticals. In 2025, organic revenue growth reached 6.7%, while international markets accounted for approximately 60% of total revenue, highlighting the company’s global business profile.
Investment attractiveness factors:
· The key revenue driver for 2026 is the combination of sustained double-digit growth in Medical Devices and the consolidation of Exact Sciences within Diagnostics. In Q1 2026, Medical Devices generated $5.5 billion in revenue, with segment growth reaching 13.2% year-over-year. Strong performance was recorded in Electrophysiology, Rhythm Management, Heart Failure, and Diabetes Care. The main product catalyst is the broader rollout of Volt PFA and TactiFlex Duo in electrophysiology. Management expects growth acceleration as commercial adoption of the catheter portfolio expands.
· An additional growth driver is Exact Sciences, which is expected to contribute approximately $3 billion in revenue to Abbott in 2026 and position the company in the rapidly growing cancer diagnostics market through products such as Cologuard, Oncotype DX, and Cancerguard. Looking ahead to 2026–2027, portfolio expansion potential is linked not only to Exact but also to the Medical Devices pipeline in pulse field ablation, transcatheter aortic valve replacement, leadless pacing, mitral valve replacement, and wearable lactate monitoring technologies.
· The margin outlook remains mixed, although structurally there is still room for improvement. Margin pressure comes from the integration of Exact Sciences, tariffs, currency fluctuations, and growth investments. However, Abbott has already demonstrated its ability to improve profitability: in 2025, operating margin expanded by 100 basis points despite tariff-related pressure. In 2026, earnings should benefit from operating leverage in the second half of the year, recovery in the Nutrition segment following pricing and promotional initiatives, and growth in laboratory diagnostics. The negative EPS impact of $0.20 related to the Exact acquisition is viewed as a one-time pressure factor.
· The decline in the stock appears to reflect reduced short-term expectations rather than deterioration in the company’s fundamentals. Following the earnings report, shares fell because Q2 EPS guidance of $1.25–$1.31 came in below consensus expectations, while full-year 2026 EPS guidance was lowered due to Exact Sciences. We believe the selloff was excessive: Q1 results were broadly in line with expectations, revenue and EPS slightly exceeded consensus, Medical Devices growth remains strong, and Exact adds a new long-term growth vector. Current valuation at 15.8x NTM P/E corresponds to 10-year lows and remains significantly below the post-COVID range of 20–25x. We view current levels as an attractive entry point for a long-term position in ABT. Target price: $120